Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus : A post-hoc analysis of a 52-week randomised trial

Show full item record



Permalink

http://hdl.handle.net/10138/315644

Citation

Muskiet , M H A , Bunck , M C , Heine , R J , Corner , A , Yki-Järvinen , H , Eliasson , B , Joles , J A , Diamant , M , Tonneijck , L & van Raalte , D H 2019 , ' Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus : A post-hoc analysis of a 52-week randomised trial ' , Diabetes Research and Clinical Practice , vol. 153 , pp. 14-22 . https://doi.org/10.1016/j.diabres.2019.05.001

Title: Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus : A post-hoc analysis of a 52-week randomised trial
Author: Muskiet, M. H. A.; Bunck, M. C.; Heine, R. J.; Corner, A.; Yki-Järvinen, H.; Eliasson, B.; Joles, J. A.; Diamant, M.; Tonneijck, L.; van Raalte, D. H.
Contributor: University of Helsinki, Diabetes and Obesity Research Program
University of Helsinki, HUS Internal Medicine and Rehabilitation
Date: 2019-07
Language: eng
Number of pages: 9
Belongs to series: Diabetes Research and Clinical Practice
ISSN: 0168-8227
URI: http://hdl.handle.net/10138/315644
Abstract: Aims: To compare the effects of long-term treatment with the GLP-1RA exenatide twicedaily versus titrated insulin glargine (iGlar) on renal function and albuminuria in type 2 diabetes (T2DM) patients. Methods: We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean +/- SD age 60 +/- 8 years, HbA1c 7.5 +/- 0.9%, eGFR 86 +/- 16 mL/min/1.73m(2), median [IQR] urinary albumin-to-creatinine-ratio (UACR) 0.75 [0.44-1.29] mg/mmol) randomised to exenatide 10 mg twice-daily or titrated iGlar on-top-of metformin for 52-weeks. Renal efficacy endpoints were change in creatinine clearance (CrCl) and albuminuria (urinary albuminexcretion [UAE] and UACR) based on 24-h urines, collected at baseline and Week-52. eGFR and exploratory endpoints were collected throughout the intervention-period, and after a 4-week wash-out. Results: HbA1c-reductions were similar with exenatide (mean +/- SEM -0.80 +/- 0.10%) and iGlar (-0.79 +/- 0.14%; treatment-difference 0.02%; 95% CI - 0.31 to 0.42%). Change from baseline to Week-52 in CrCl, UAE or UACR did not statistically differ; only iGlar reduced albuminuria (P <0.05; within-group). eGFR decreased from baseline to Week-4 with exenatide (-3.9 +/- 2.1 mL/min/1.73 m(2); P = 0.069) and iGlar (-2.7 +/- 1.2 mL/min/1.73 m(2); P = 0.034), without treatment-differences in ensuing trajectory. Exenatide versus iGlar reduced bodyweight (-5.4 kg; 2.9-7.9; P <0.001), but did not affect blood pressure, lipids or plasma uric acid. Conclusions: Among T2DM patients without overt nephropathy, one-year treatment with exenatide twice-daily does not affect renal function-decline or onset/progression of albuminuria compared to titrated iGlar. (C) 2019 Elsevier B.V. All rights reserved.
Subject: GLP-1 receptor agonist
Exenatide
Insulin glargine
Albuminuria
Glomerular filtration rate
Diabetic kidney disease
Renoprotection
Type 2 diabetes mellitus
KIDNEY-FUNCTION
CARDIOVASCULAR OUTCOMES
DOUBLE-BLIND
LIRAGLUTIDE
GLP-1
LIXISENATIDE
MECHANISMS
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Exenatide_twice ... a_post_hoc_analysis_of.pdf 705.7Kb PDF View/Open
1_s2.0_S0168822719301925_main.pdf 1.266Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record